AlcoChange is a Digital therapeutic intended to reduce alcohol use and maintain abstinence in individuals with established alcohol-related liver disease (ArLD)
Indications for Use
AlcoChange is intended to provide behavioral therapy based on CyberLiver Behaviour Change (CBC) Model that is designed from the blend of principles from Various behaviour change theories in the design of Digital Behaviour Change Techniques (DBCTs), Digital Behaviour Change Interventions (DBCI’s). Personalised Motifications (motivational messages and interactions) are designed following the FRAMES model, consisting of Feedback, Responsibility, Advise, Menu for change, Empathy, and enhancing Self-efficacy.
AlcoChange, as an adjunct to a contingency management system, for patients 18 years of age and older who are currently enrolled in outpatient treatment under the supervision of a clinician. AlcoChange is indicated as 90 days or 180 days prescription-only treatment for patients with Alcohol-Related Liver Disease. It is intended to increase abstinence and increase retention in the outpatient treatment program.
It is intended to:
increase abstinence and increase retention in the outpatient treatment program, and increase retention in the outpatient treatment program.